tiprankstipranks
Broncus Holding Corp. (HK:2216)
:2216
Hong Kong Market
Want to see HK:2216 full AI Analyst Report?

Broncus Holding Corp. (2216) Price & Analysis

0 Followers

2216 Stock Chart & Stats

HK$2.36
HK$0.01(1.61%)
At close: 4:00 PM EST
HK$2.36
HK$0.01(1.61%)

Bulls Say, Bears Say

Bulls Say
Low Leverage / Strong EquityExtremely low leverage and sizable positive equity materially reduce refinancing risk and provide durable financial flexibility. This balance-sheet strength gives the company a runway to fund operations, R&D or restructuring and absorb operating volatility over several months.
Historic Gross Margin StrengthEarlier periods of solid gross margins indicate the underlying device economics can support profitability at scale. If commercial traction is restored, fixed-cost leverage and historically healthy unit margins could enable a sustainable margin recovery, a structural advantage.
Improving Cash Flow TrendThe less-negative free cash flow in the latest year signals an improving cash-burn trajectory. While still negative, a sustained reduction in cash outflow eases near-term funding pressure and, if continued, can enable incremental self-funding of operations and commercialization activities over months.
Bears Say
Severe Revenue CollapseA ~97% YoY revenue decline reflects catastrophic loss of commercial traction and scale. Such a collapse undermines pricing power, channel relationships and cost absorption. Restoring meaningful revenue will likely require multiple quarters of execution and constrains durable profitability prospects.
Consistent Cash BurnPersistent negative operating and free cash flow across all reported years indicates chronic cash burn. This forces reliance on external financing, increases dilution or refinancing risk, and limits the company’s ability to sustainably invest in sales, clinical or regulatory milestones over the medium term.
Persistent Losses & Negative ROEOngoing large operating and net losses produce negative returns on equity despite positive equity balances. Persistent unprofitability erodes shareholder value, makes capital raising more costly, and signals structural issues in the commercial model or cost base that must be addressed for long-term viability.

Broncus Holding Corp. News

2216 FAQ

What was Broncus Holding Corp.’s price range in the past 12 months?
Broncus Holding Corp. lowest stock price was HK$1.00 and its highest was HK$3.72 in the past 12 months.
    What is Broncus Holding Corp.’s market cap?
    Broncus Holding Corp.’s market cap is HK$666.21M.
      When is Broncus Holding Corp.’s upcoming earnings report date?
      Broncus Holding Corp.’s upcoming earnings report date is Aug 27, 2026 which is in 120 days.
        How were Broncus Holding Corp.’s earnings last quarter?
        Currently, no data Available
        Is Broncus Holding Corp. overvalued?
        According to Wall Street analysts Broncus Holding Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Broncus Holding Corp. pay dividends?
          Broncus Holding Corp. does not currently pay dividends.
          What is Broncus Holding Corp.’s EPS estimate?
          Broncus Holding Corp.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Broncus Holding Corp. have?
          Broncus Holding Corp. has 528,737,060 shares outstanding.
            What happened to Broncus Holding Corp.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Broncus Holding Corp.?
            Currently, no hedge funds are holding shares in HK:2216
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Broncus Holding Corp. Stock Smart Score

              Company Description

              Broncus Holding Corp.

              Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

              Broncus Holding Corp. (2216) Earnings & Revenues

              Similar Stocks
              Company
              Price & Change
              Follow
              MicroPort CardioFlow Medtech Corp.
              Suzhou Basecare Medical Corp. Ltd. Class H
              MicroTech Medical (Hangzhou) Co., Ltd. Class H
              Venus Medtech (Hangzhou), Inc. Class H
              Shanghai Heartcare Medical Technology Corp. Ltd. Class H

              Options Prices

              Currently, No data available
              ---
              Popular Stocks